---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-24-000032"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:02:40.177604+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agios Q4 net loss $95.9M; positive mitapivat Phase 3 for NTD thalassemia

## Summary
- Q4 PYRUKYND US net revenue $7.1M (down 4% QoQ); full year 2023 $26.8M.
- Net loss $95.9M in Q4 vs net income $36.5M in Q4 2022; full year loss $352.1M.
- Positive Phase 3 ENERGIZE study in non-transfusion-dependent thalassemia met primary endpoint.
- Cash & equivalents $806.4M; company expects runway into 2026.
- Pipeline milestones: ENERGIZE-T data mid-2024; FDA filing for mitapivat in thalassemia end-2024.

## SEC filing metadata
- accession: 0001439222-24-000032
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/0001439222-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/agio-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-24-000032
- JSON: https://secwatch.observer/filing/0001439222-24-000032.json
- Plain text: https://secwatch.observer/filing/0001439222-24-000032.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 15, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/0001439222-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.